Viktor Grünwald

Director

University Hospital Essen
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app [...]

Year:

2026

Year:

2025

Year:

2025

Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc analysis of tumor response data based on baseline metastatic characteristics of patients who received lenvatinib plus pembrolizumab versus sunitinib, at the final overall survival analysis time point of CLEAR (cutoff: July 31, 2022). Treatment‐naïve adults with aRCC were randomized to: lenvatinib (20 mg PO QD in 21‐day cycles) plus pembrolizumab ( n = 355; 200 mg IV Q3W); lenvatinib plus everolimus (not reported here); or sunitinib ( n = 357; 50 mg PO QD; 4 weeks on/2 weeks off). The most common (lenvatinib plus pembrolizumab; sunitinib, respectively) metastatic site was lung (71.0%; 63.9%), followed by lymph node (45.6%; 43.7%), bone (22.5%; 24.9%), and liver (17.7%; 19.6%). Across treatment arms, ≥65% had two or more metastatic organs/sites involved, >80% of patients had nontarget lesions, and ~45% had baseline sums of diameters of target lesions ≥60 mm. Lenvatinib plus pembrolizumab demonstrated greater progression‐free survival, objective response rate, and duration of response versus sunitinib across evaluable subgroups regardless of site or size of baseline metastasis or number of metastatic sites at baseline. Overall survival generally trended to favor lenvatinib plus pembrolizumab versus sunitinib; and tumor shrinkage was greater across sites (lung, lymph node, liver, and bone) for patients in the lenvatinib‐plus‐pembrolizumab arm versus the sunitinib arm. These results further support lenvatinib plus pembrolizumab as a standard‐of‐care in patients with aRCC regardless of site or size of baseline metastasis or the number of metastatic sites.

Year:

2025

Background: The efficacy and safety of tivozanib for the treatment of advanced or metastatic renal cell carcinoma (mRCC) have been established in the first-line setting in the Phase III trial TIVO-1. Methods: The prospective T-Rex study conducted in German clinical practice evaluated the safety, effectiveness and impact on quality of life (QoL) of first-line treatment with tivozanib in 32 patients with mRCC recruited between May 2019 and April 2021. Results: Recruited patients were predominantly elderly, with 53.1% aged over 75 years. Patients received a median of 6.5 tivozanib treatment cycles and the median time on treatment was 5.7 months. Overall, 78.1% of patients experienced treatment-related adverse events, including diarrhea, nausea and hypotension/hypertension. A clinical (i.e., complete or partial) response was observed in 46.9% of patients. Patients’ QoL remained stable from baseline to the end of treatment and most symptomatic toxicities resolved by the final treatment cycle, with the exclusion of dry skin, itching, and hand–foot syndrome. Conclusions: These data demonstrate that first-line treatment with tivozanib was associated with clinical activity, favorable tolerability, and stable QoL in patients with mRCC treated in everyday clinical practice across Germany, including those with advanced age.

Year:

2025

Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.

Year:

2025

Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.

Year:

2025

Background: Urothelial carcinoma (UC) is a significant global health burden and shows consistent increase in incidence. The treatment landscape for advanced or metastatic urothelial carcinoma (mUC) has evolved, but significant challenges remain to prolong survival. The article is based on the content of the recent guidelines and a selective literature search. Summary: For many years in the past, cisplatin-based chemotherapy was the standard first-line therapy for eligible patients. But chemotherapy alone provides limited long-term benefit, and a large proportion of patients either progress rapidly or are ineligible for cisplatin due to comorbidities. This demonstrates the medical need and led to the development of immune checkpoint inhibitors and antibody-drug conjugates (ADCs) in the field of mUC treatment. More recently, the introduction of ADCs further enlarged the medical armamentarium in mUC patients and was further explored as combined regimens. The combination of enfortumab vedotin (EV) and pembrolizumab was superior to standard platin-based chemotherapy as did nivolumab plus gemcitabine with cisplatin, which permanently transformed the medical treatment landscape in mUC. Today, EV plus pembrolizumab is the first-line standard in treatment of therapeutic advanced or mUC. New options are also emerging, such as molecular therapies that target the fibroblast growth factor receptor. In the future, targeted therapy could also be used in the perioperative area. Key Message: Today, EV combined with pembrolizumab sets a new standard of care in medical treatment of a/mUC patients. Compared to platinum-based therapy, EV plus pembrolizumab doubled the overall survival probability and reported a median OS of 31.5 months, which is a new hallmark of palliative medical treatment in this disease. This novel therapy in combination with molecular therapies, novel devices, and molecular markers offers a great opportunity for the next step in medical development in localized UC, and its clinical applicability is being investigated in ongoing studies.

Year:

2025

PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

Year:

2025

Zusammenfassung Hintergrund Immunmodulatorische Therapien gewinnen immer größere Bedeutung in der Uro-Onkologie. Aus diesem Grund werden wir vermutlich immer häufiger mit Nebenwirkungen konfrontiert werden. Hinzu kommt eine immer größere Zahl an Kombinationen mit anderen Wirkmechanismen. Als Folge dieser Therapie können immun-vermittelte Nebenwirkungen auftreten. Diese unterscheiden sich von den Nebenwirkungen einer Chemotherapie und anderen zielgerichteten Therapien und erfordern daher andere Behandlungsstrategien. Ziel der Arbeit Anhand der aktuellen Literatur werden die Daten zur Graduierung und stadienabhängigen Management dargelegt sowie mit Beispielen aus der Praxis anschaulich dargestellt. Material und Methoden Literaturrecherche zur Detektion und Therapiemanagement von im Rahmen der immunonkologischen Therapie vermittelten Nebenwirkungen. Ergebnisse Die behandlungsbezogenen Ereignisse können prinzipiell alle Organsystem betreffen, häufig sehen finden sich Toxizitäten im Bereich der Haut, wie Ausschlag oder Pruritus, Hypo- oder Hyperthyreosen, Arthritiden, Muskelschmerzen und gastrointestinale Symptome. In der Häufigkeit sind die meisten Nebenwirkungen Grad 1 bis 2 zuzuordnen, jedoch auch Grad 3 bis 4 Toxizitäten sind grundsätzlich gut zu therapieren, sofern sie frühzeitig erkannt werden. Seltene Komplikationen wie neurologische Toxizitäten, Pneumonitis oder auch Karditis können bei zu später Diagnose einen fulminanten Verlauf entwickeln. Diskussion Selbst Notfälle sind gut zu managen, wenn wir die wichtigsten Nebenwirkungen und therapeutischen Optionen kennen. Dabei kommt den immunvermittelten Nebenwirkungen ein besonderer Stellenwert zu, weil sie grundsätzlich jedes Organsystem betreffen können. So lange wir jedoch bei Patienten, die Symptome zeigen, an die Möglichkeit einer Toxizität durch Checkpointinhibitoren denken, sind die meisten Nebenwirkungen gut zu therapieren und daher kontrollierbar.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Michael Hölzel

Director/MD, Professor

University Hospital Bonn

GERMANY
View details

Niklas Klümper

University Hospital Bonn

GERMANY
View details

Glen Kristiansen

-

GERMANY
View details

Philipp Erben

Laboratory Head

University Medical Centre Mannheim

GERMANY
View details

Oliver Hahn

Attending urologist

University Hospital Würzburg

GERMANY
View details

Jörg Ellinger

University Hospital Bonn

GERMANY
View details

Stephen L George

Duke University School of Medicine

UNITED STATES
View details

Brian Shuch

University of California

UNITED STATES
View details

Kristina Schwamborn

Technical University of Munich

GERMANY
View details

Axel Bex

Head of Department

Amsterdam University Medical Center

NETHERLANDS
View details

Wilko Weichert

University Hospital Heidelberg

GERMANY
View details

Steffen Rausch

University Hospital Tübingen

GERMANY
View details